Moore Capital Management’s Revolution Medicines RVMD Stock Holding History

Moore Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.3M	Buy	81,700 +26,100	+47%	+$3.81M	0.23%	83
2026 Q1	$5.41M	Hold	55,600	–	–	0.11%	147
2025 Q4	$4.43M	Hold	55,600	–	–	0.06%	274
2025 Q3	$2.6M	Hold	55,600	–	–	0.04%	328
2025 Q2	$2.05M	Hold	55,600	–	–	0.03%	325
2025 Q1	$1.97M	Hold	55,600	–	–	0.04%	268
2024 Q4	$2.43M	Hold	55,600	–	–	0.03%	308
2024 Q3	$2.52M	Hold	55,600	–	–	0.05%	281
2024 Q2	$2.16M	Hold	55,600	–	–	0.04%	265
2024 Q1	$1.79M	Hold	55,600	–	–	0.03%	272
2023 Q4	$1.59M	Buy	+55,600	New	+$1.34M	0.03%	246

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Moore Capital Management's RVMD Position: Q2 2026 in Review

Moore Capital Management increased its Revolution Medicines (RVMD) stake by 47% in Q2 2026, buying an estimated $3.81M and bringing the position to 81,700 shares worth $15.3M. The position accounts for 0.23% of the portfolio, ranked #83.

Moore Capital Management first reported a position in RVMD in Q4 2023 and has held it in 11 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Moore Capital Management held 81,700 shares of Revolution Medicines worth $15.3M as of Q2 2026.
Moore Capital Management bought 26,100 Revolution Medicines shares in Q2 2026, an estimated $3.81M.
Revolution Medicines made up 0.23% of Moore Capital Management's portfolio in Q2 2026, its #83 holding.
Moore Capital Management first reported a position in Revolution Medicines in Q4 2023 and has held it in 11 quarters since.
690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.